Characterization and management of adverse reactions (ARs) in patients with advanced renal cell carcinoma (aRCC) receiving lenvatinib plus pembrolizumab (CLEAR study)

被引：0
|
作者：
Motzer, Robert [1 ]
George, Saby [2 ]
Merchan, Jaime R. [3 ]
Hutson, Thomas E. [4 ,5 ]
Song, Xun [6 ]
Perini, Rodolfo F. [6 ]
Xie, Ran [7 ]
Bapat, Urmi [7 ]
Ebaid, Basant [8 ]
Puente, Javier [9 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA
[2] Roswell Park Comprehens Canc Ctr, Dept Med, Buffalo, NY USA
[3] Univ Miami, Dept Med, Sylvester Comprehens Canc Ctr, Miami, FL USA
[4] Baylor Charles A Sammons Canc Ctr, Dept Med Oncol, Texas Oncol, Dallas, TX USA
[5] Texas A&M HSC Coll Med, Bryan, TX USA
[6] Merck & Co Inc, Rahway, NJ 07065 USA
[7] Eisai Inc, Nutley, NJ USA
[8] Eisai Australia Pty Ltd, Melbourne, Vic, Australia
[9] Hosp Clin Univ San Carlos, Dept Med Oncol, Madrid, Spain
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
196
引用
收藏
页码：121 / 122
页数：2
相关论文
共 50 条
  • [1] Characterization and Management of Adverse Reactions From the CLEAR Study in Advanced Renal Cell Carcinoma Treated With Lenvatinib Plus Pembrolizumab
    Motzer, Robert
    George, Saby
    Merchan, Jaime R.
    Hutson, Thomas E.
    Song, Xun
    Perini, Rodolfo F.
    Xie, Ran
    Bapat, Urmi
    Puente, Javier
    ONCOLOGIST, 2023, 28 (06): : 501 - 509
  • [2] Characterization and Management of Adverse Reactions in Patients With Advanced Endometrial Cancer Receiving Lenvatinib Plus Pembrolizumab
    Colombo, Nicoletta
    Lorusso, Domenica
    Monk, Bradley J.
    Slomovitz, Brian
    Hasegawa, Kosei
    Nogueira-Rodrigues, Angelica
    Zale, Melissa
    Okpara, Chinyere E.
    Barresi, Gianmaria
    McKenzie, Jodi
    Makker, Vicky
    ONCOLOGIST, 2024, 29 (01): : 25 - 35
  • [3] Characterization and Management of Adverse Reactions in Patients with Advanced Endometrial Carcinoma Treated with Lenvatinib Plus Pembrolizumab
    Makker, Vicky
    Taylor, Matthew H.
    Oaknin, Ana
    Casado Herraez, Antonio
    Orlowski, Robert
    Dutta, Lea
    Ren, Min
    Zale, Melissa
    O'Malley, David M.
    ONCOLOGIST, 2021, 26 (09): : E1599 - E1608
  • [4] Impact of subsequent therapies in patients (pts) with advanced renal cell carcinoma (aRCC) receiving lenvatinib plus pembrolizumab (LEN plus PEMBRO) or sunitinib (SUN) in the CLEAR study.
    Voss, Martin H.
    Powles, Thomas
    McGregor, Bradley Alexander
    Porta, Camillo
    Gruenwald, Viktor
    Merchan, Jaime R.
    Rolland, Frederic
    Maroto-Rey, Pablo
    Goh, Jeffrey C.
    Xing, Dongyuan
    Perini, Rodolfo F.
    McKenzie, Jodi
    Mody, Kalgi
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [5] Updated efficacy of lenvatinib (LEN) plus pembrolizumab (PEMBRO) versus sunitinib (SUN) in patients with advanced renal cell carcinoma (aRCC) in the CLEAR study
    Porta, Camillo G.
    Eto, Masatoshi
    Motzer, Robert J.
    De Giorgi, Ugo
    Buchler, Tomas
    Basappa, Naveen S.
    Mendez Vidal, Maria Jose
    Tjulandin, Sergei
    Park, Se Hoon
    Melichar, Bohuslav
    Hutson, Thomas
    Alemany, Carlos
    McGregor, Bradley
    He, Cixin Steven
    Perini, Rodolfo
    Mody, Kalgi
    McKenzie, Jodi
    Ebaid, Basant
    Choueiri, Toni
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 122 - 123
  • [6] Management of Adverse Reactions Related to Lenvatinib Plus Pembrolizumab Treatment Among Patients With Renal Cell Carcinoma
    Gruenwald, Viktor
    Larkin, James
    Puente, Javier
    Bedke, Jens
    Porta, Camillo
    CLINICAL GENITOURINARY CANCER, 2024, 22 (02) : 394 - 401
  • [7] Updated efficacy of lenvatinib (LEN) plus pembrolizumab (PEMBRO) vs sunitinib (SUN) in patients (pts) with advanced renal cell carcinoma (aRCC) in the CLEAR study
    Porta, C. G.
    Eto, M.
    Motzer, R. J.
    De Giorgi, U. F. F.
    Buchler, T.
    Basappa, N. S.
    Mendez Vidal, M. J.
    Tjulandin, S.
    Park, S. H.
    Melichar, B.
    Hutson, T. E.
    Alemany, C.
    McGregor, B.
    He, C. S.
    Perini, R.
    Mody, K.
    McKenzie, J.
    Choueiri, T. K.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1205 - +
  • [8] Lenvatinib plus pembrolizumab versus sunitinib for advanced renal cell carcinoma: Japanese patients from the CLEAR study
    Eto, Masatoshi
    Takagi, Toshio
    Kimura, Go
    Fukasawa, Satoshi
    Tamada, Satoshi
    Miura, Yuji
    Oya, Mototsugu
    Sassa, Naoto
    Anai, Satoshi
    Nozawa, Masahiro
    Sakai, Hideki
    Perini, Rodolfo
    Yusa, Wataru
    Ikezawa, Hiroki
    Narita, Tomoyuki
    Tomita, Yoshihiko
    CANCER MEDICINE, 2023, 12 (06): : 6902 - 6912
  • [9] Characteristics and management of major adverse events in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab based on results from the CLEAR trial
    Motzer, R.
    George, S.
    Merchan, J. R.
    Hutson, T. E.
    Song, X.
    Perini, R. F.
    Xie, R.
    Bapat, U.
    Puente, J.
    ONKOUROLOGIYA, 2023, 19 (02): : 29 - 40
  • [10] Characterization of Responses to Lenvatinib plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma at the Final Prespecified Survival Analysis of the Phase 3 CLEAR Study
    Motzer, Robert J.
    Choueiri, Toni K.
    Hutson, Thomas
    Rha, Sun Young
    Puente, Javier
    Lalani, Aly-Khan A.
    Winquist, Eric
    Eto, Masatoshi
    Basappa, Naveen S.
    Tannir, Nizar M.
    Vaishampayan, Ulka
    Bjarnason, Georg A.
    Oudard, Stephane
    Gruenwald, Viktor
    Burgents, Joseph
    Xie, Ran
    McKenzie, Jodi
    Powles, Thomas
    EUROPEAN UROLOGY, 2024, 86 (01) : 4 - 9
12345